695 related articles for article (PubMed ID: 15701206)
1. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
[TBL] [Abstract][Full Text] [Related]
2. Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
Zhu B; Ascher-Svanum H; Faries DE; Correll CU; Kane JM
BMC Psychiatry; 2008 Apr; 8():19. PubMed ID: 18394168
[TBL] [Abstract][Full Text] [Related]
3. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine.
Gianfrancesco F; Pesa J; Wang RH
J Manag Care Pharm; 2005 Apr; 11(3):220-30. PubMed ID: 15804206
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
[TBL] [Abstract][Full Text] [Related]
5. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
[TBL] [Abstract][Full Text] [Related]
6. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Jing Y; Kim E; You M; Pikalov A; Tran QV
J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
[TBL] [Abstract][Full Text] [Related]
7. Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.
Yu AP; Atanasov P; Ben-Hamadi R; Birnbaum H; Stensland MD; Philips G
Value Health; 2009; 12(5):708-15. PubMed ID: 19508658
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
9. Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.
Lucey JV; Libretto SE
Ir J Med Sci; 2003; 172(4):195-201. PubMed ID: 15029989
[TBL] [Abstract][Full Text] [Related]
10. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
Taylor DM; Wright T; Libretto SE;
J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
[TBL] [Abstract][Full Text] [Related]
11. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
Yu W; Ren XS; Lee AF; Herz L; Huang YH; Kazis LE
Pharmacoeconomics; 2006; 24(12):1233-48. PubMed ID: 17129077
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China.
Yang L; Li M; Tao LB; Zhang M; Nicholl MD; Dong P
Value Health; 2009; 12 Suppl 3():S66-9. PubMed ID: 20586985
[TBL] [Abstract][Full Text] [Related]
13. Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder.
Zhu B; Kulkarni PM; Stensland MD; Ascher-Svanum H
Curr Med Res Opin; 2007 Nov; 23(11):2805-14. PubMed ID: 17910804
[TBL] [Abstract][Full Text] [Related]
14. Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.
Law WL; Hui HY; Young WM; You JH
Int J Clin Pharmacol Ther; 2007 May; 45(5):264-70. PubMed ID: 17542348
[TBL] [Abstract][Full Text] [Related]
15. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia.
Chen L; McCombs JS; Park J
Value Health; 2008; 11(1):34-43. PubMed ID: 18237358
[TBL] [Abstract][Full Text] [Related]
16. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.
Zhao Z
Curr Med Res Opin; 2004 Jul; 20(7):1039-48. PubMed ID: 15265249
[TBL] [Abstract][Full Text] [Related]
17. Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.
Kopala L; Smith G; Malla A; Williams R; Love L; Talling D; Balshaw R
Acta Psychiatr Scand Suppl; 2006; (430):29-39. PubMed ID: 16542323
[TBL] [Abstract][Full Text] [Related]
18. Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorders and Alzheimer's disease.
Edell WS; Rupnow MF
Manag Care Interface; 2003 May; 16(5):64-7. PubMed ID: 12789866
[TBL] [Abstract][Full Text] [Related]
19. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
20. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
